GlycoMimetics Inc - Asset Resilience Ratio
GlycoMimetics Inc (GLYC) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is GlycoMimetics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2017)
This chart shows how GlycoMimetics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see GlycoMimetics Inc (GLYC) total assets.
Liquid Assets Composition Over Time
This chart breaks down GlycoMimetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read GLYC liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: GlycoMimetics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
GlycoMimetics Inc Industry Peers by Asset Resilience Ratio
Compare GlycoMimetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for GlycoMimetics Inc (2011–2017)
The table below shows the annual Asset Resilience Ratio data for GlycoMimetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $128.58 Million | -- |
| 2016-12-31 | 0.03% | $10.65K | $42.39 Million | +0.01pp |
| 2015-12-31 | 0.02% | $9.27K | $48.46 Million | -0.01pp |
| 2014-12-31 | 0.03% | $16.29K | $57.26 Million | +0.01pp |
| 2013-12-31 | 0.02% | $1.00K | $5.28 Million | -0.43pp |
| 2012-12-31 | 0.45% | $83.00K | $18.42 Million | +0.20pp |
| 2011-12-31 | 0.25% | $73.00K | $28.91 Million | -- |
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.